Inhibiting leukocyte recruitment to the brain by IVIg: Is it relevant to the treatment of demyelinating CNS disorders?

Brain

Volumn 127, Issue 12, 2004, Pages 2569-2571

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; NATALIZUMAB;

AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DEMYELINATING DISEASE; DEMYELINATING NEUROPATHY; HUMAN; LEUKOCYTE MIGRATION; MULTIPLE SCLEROSIS; NOTE; PRIORITY JOURNAL; STIFF MAN SYNDROME; T LYMPHOCYTE;

EID: 10344238643     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh343     Document Type: Note

References (10)

1. Alter A, Duddy M, Hebert S, Biernacki K, Prat A, Antel JP, Yong VW, Nuttal RK, Pennington CJ, Edwards DR, Bar-Or A. Determinants of human B cell migration across brain endothelial cells. J Immunol 2003; 70: 4497-4505.
2. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. J Am Med Assoc 2004a; 291: 2367-2375.
3. Dalakas MC. The role of IVIg in the treatment of autoimmune neurological disorders: evidence based indications and safety profile. Pharmacol Ther 2004b; 102: 177-193.
4. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.
5. Kubes P, Ward PA. Leukocyte recruitment and the acute inflammatory response. Brain Pathol 2000; 10: 127-35.
6. Lapointe BM, Herx LM, Gill, V, Metz LM, Kubes P. IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain. In press 2004.
7. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
8. Ransohoff RM, Kivisäkk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Immunol 2003; 3: 569-81.
9. Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 2002; 9: 557-63.
10. von Andrian UH, MacKay CR. T-cell function and migration: two sides of the same coin. N Engl J Med 2000; 343: 1020-34.